关于在牛皮中使用含有皮质类固醇的局部药物的共识声明
Journal of drugs in dermatology : JDD
|August 9, 2023
概括
专家皮肤科医生制定了关于用皮质类固醇局部药物治疗牛皮的共识陈述. 他们同意首选的治疗方法,平衡疗效,患者经验和安全性,以更好地治疗牛皮.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮的治疗严重依赖于局部治疗.
- 局部皮质类固醇是牛皮治疗的基石,但最佳使用需要明确的指导.
研究的目的:
- 建立关于使用含有皮质类固醇的局部药物治疗牛皮的共识陈述.
- 为优化局部牛皮治疗提供专家驱动的建议.
主要方法:
- 一个经过修改的Delphi工艺,涉及皮肤病专家组 (PEG) 的皮肤病专家.
- 进行了两轮投票,以在局部药物使用的各个方面达成小组共识.
主要成果:
- 开发了9个共识陈述,涵盖了疗效,生活质量,应用频率,药物感觉和安全性.
- 大多数声明都达到了高度共识,这反映了专家之间的强烈共识.
- 专家们一致认为,患者和医生更喜欢有效的局部治疗方法,其开始迅速,皮肤感觉良好,副作用最小.
结论:
- 达成共识的声明为皮病的局部治疗提供了实际指导.
- 建议包括考虑组合疗法,例如与局部皮质类固醇的维生素D类似物.
- 这些指南将随着新证据的出现而更新,以确保目前的牛皮护理最佳实践.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
299
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
299
COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173


